ELISA Kit for Chymase 1, Mast Cell (CMA1)

31.2-2, 000pg/mL

The minimum detectable dose of this kit is typically less than 12.1pg/mL

3h

This assay has high sensitivity and excellent specificity for detection of Chymase 1, Mast Cell (CMA1).
No significant cross-reactivity or interference between Chymase 1, Mast Cell (CMA1) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Chymase 1, Mast Cell (CMA1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Chymase 1, Mast Cell (CMA1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Chymase 1, Mast Cell (CMA1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Chymase 1, Mast Cell (CMA1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Diabetes-associated angiotensin activation enhances liver metastasis of colon cancer; Mediators of Mast Cells in Bullous Pemphigoid andDermatitis Herpetiformis; Peritoneal mast cell degranulation and gastrointestinal recovery in patients undergoing colorectal surgery; Vasoactive intestinal peptide degradation might influence Interleukin-17 expression in cardiac chagasic patients;